Moderna, Inc. Common Stock vs. Surrozen, Inc. Common
Moderna, Inc. Common Stock and Surrozen, Inc. Common are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| MRNA | SRZN | |
|---|---|---|
| Market Cap | $72.70 billion | $189.94 million |
| Revenue (TTM) | $2.23 billion | $11.51 million |
| Net Income (TTM) | $-3,151,000,000 | $-332,130,000 |
MRNA leads on 2 of 3 size & scale factors.
Valuation
| MRNA | SRZN | |
|---|---|---|
| Price / Book | 10.75 | -0.87 |
| Price / Sales | 32.63 | 16.50 |
SRZN leads on 2 of 2 valuation factors.
Profitability
| MRNA | SRZN | |
|---|---|---|
| Net Margin | -141.43% | -2885.33% |
| Return on Equity | -46.61% | 151.89% |
MRNA and SRZN split the profitability factors evenly.
Risk & Sentiment
| MRNA | SRZN | |
|---|---|---|
| Short Interest | 0.01% | 0.33% |
MRNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MRNA overview, MRNA financials, SRZN overview, SRZN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.